Alogliptin: summary of product characteristics
Christoffersen B, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E
Absolute risk remained low: 0.29% with semaglutide compared with 0.13% with an SGLT2i
Percent change in weight from baseline and proportion of patients achieving a weight loss of 5% were the co-primary endpoints
WellMedr's own source materials state: "Compounded medications offered through Wellmedr are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality." That is accurate regulatory language
October 2, 2025: Mounjaro Green Lit for Children Ages 10+ with Type 2 Diabetes Eli Lilly has received approval to recommend Mounjaro to help children between 10 and 17 manage their Type 2 diabetes